Iris Pharma and Clirophtha Merger Creates Unique Ophthalmology CRO
"The merger of Iris Pharma and Clirophtha is an opportunity to increase pharmaceutical and biotech companies' ability to develop the potential of their ophthalmologic drugs," says Dr Pierre-Paul Elena, Founder and CEO of Iris Pharma.
The combined company will operate under the Iris Pharma name. This merger establishes the first global drug-development services provider to be totally dedicated to ophthalmology, offering a complete range of services to biotechnology and pharmaceutical companies worldwide.
"The cumulative expertise and experience from both companies guarantees that the new Iris Pharma company has excellent know-how and knowledge of each step of drug development, from pre-formulation and in vivo research to Phase IV and medico-marketing surveys, as well as a global overview of the whole process," says Thierry Caillaud, Business Development Director of Iris Pharma.
The companies' combined experience totals 31 years, with staff's experience representing a combined total in excess of 260 years. This expertise will provide a one-stop solution for clients' ophthalmology drug and device development; it will also create significant benefits for customers in terms of flexibility and efficiency.
"Our focus is on continuing to provide our customers with the best quality service and the best level of responsiveness. Our expertise and experience in ophthalmology guarantee our customers accurate consulting services at every stage of drug development. We are more than a simple supplier - we act as a dedicated partner in helping our clients to take the right decision, at the right moment, to move forward efficiently and market their drugs faster," says Yann Quentric, Business Development Director of Clirophtha.
About Iris Pharma
Iris Pharma, which is headquartered near Nice, France, is an independent development service provider, dedicated to pre-clinical and clinical research in ophthalmology. Since 1989, it has been offering ophthalmologic drug and device development services to pharmaceutical and biotechnology companies worldwide. The company works in five complementary areas: bioanalysis; non-GLP pre-formulation; pre-clinical studies and services; clinical trials (Phase I to IV); and strategic consulting.
Posted: January 2008
Recommended for you